BACKGROUND AND PURPOSE: The Val66Met polymorphism of brain-derived neurotrophic factor is associated with decreased brain-derived neurotrophic factor secretion and poor outcome after acute neurological injury. We hypothesized that the Met allele is associated with worsening of functional outcome after brain arteriovenous malformation resection. METHODS: Three hundred forty-one surgically treated patients with brain arteriovenous malformation with outcome data were genotyped for Val66Met. Outcome was change in modified Rankin Scale preoperatively versus postoperatively, dichotomized into poor (change >0) or good outcome (change ≤0). Likelihood ratio tests for interactions and logistic regression analysis were performed. RESULTS: A significant interaction (P=0.03) of Val66Met genotype and hemorrhagic presentation existed; thus, ruptured and unruptured patients were considered separately. The Met allele was associated with increased risk of poor outcome among patients presenting unruptured (OR, 2.15; 95% CI, 1.02-4.55; P=0.045) but not ruptured (OR, 0.54; 95% CI, 0.19-1.53; P=0.25), adjusting for covariates. CONCLUSIONS: The Val66Met polymorphism is associated with worsened surgical outcome in patients with unruptured brain arteriovenous malformation, a group that currently has no good risk predictors. Further studies replicating these findings are needed.
BACKGROUND AND PURPOSE: The Val66Met polymorphism of brain-derived neurotrophic factor is associated with decreased brain-derived neurotrophic factor secretion and poor outcome after acute neurological injury. We hypothesized that the Met allele is associated with worsening of functional outcome after brain arteriovenous malformation resection. METHODS: Three hundred forty-one surgically treated patients with brain arteriovenous malformation with outcome data were genotyped for Val66Met. Outcome was change in modified Rankin Scale preoperatively versus postoperatively, dichotomized into poor (change >0) or good outcome (change ≤0). Likelihood ratio tests for interactions and logistic regression analysis were performed. RESULTS: A significant interaction (P=0.03) of Val66Met genotype and hemorrhagic presentation existed; thus, ruptured and unruptured patients were considered separately. The Met allele was associated with increased risk of poor outcome among patients presenting unruptured (OR, 2.15; 95% CI, 1.02-4.55; P=0.045) but not ruptured (OR, 0.54; 95% CI, 0.19-1.53; P=0.25), adjusting for covariates. CONCLUSIONS: The Val66Met polymorphism is associated with worsened surgical outcome in patients with unruptured brain arteriovenous malformation, a group that currently has no good risk predictors. Further studies replicating these findings are needed.
Authors: Janneke van Beijnum; H Bart van der Worp; Dennis R Buis; Rustam Al-Shahi Salman; L Jaap Kappelle; Gabriël J E Rinkel; Jan Willem Berkelbach van der Sprenkel; W Peter Vandertop; Ale Algra; Catharina J M Klijn Journal: JAMA Date: 2011-11-09 Impact factor: 56.272
Authors: N M Oyesiku; C O Evans; S Houston; R S Darrell; J S Smith; Z L Fulop; C E Dixon; D G Stein Journal: Brain Res Date: 1999-07-03 Impact factor: 3.252
Authors: Jari Siironen; Seppo Juvela; Katarzyna Kanarek; Juhani Vilkki; Juha Hernesniemi; Jaakko Lappalainen Journal: Stroke Date: 2007-08-30 Impact factor: 7.914
Authors: Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger Journal: Cell Date: 2003-01-24 Impact factor: 41.582
Authors: Martin Helan; Bharathi Aravamudan; William R Hartman; Michael A Thompson; Bruce D Johnson; Christina M Pabelick; Y S Prakash Journal: J Mol Cell Cardiol Date: 2014-01-23 Impact factor: 5.000
Authors: Won-Seok Kim; Jong Youb Lim; Joon Ho Shin; Hye Kyung Park; Samuel Arnado Tan; Kyoung Un Park; Nam-Jong Paik Journal: Ann Rehabil Med Date: 2013-06-30